Skip to main content

Table 1 Characteristics of patients registered in ASSET-K and patients with 2-year data

From: Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study

 

Overall ASSET-K population

Patients with 2-year data

n

1332

831

Age (years)

62.9 ± 11.6

63.3 ± 10.9

Sex (male/female)

751/581

469/362

Duration of diabetes (years)

12.0 ± 8.1

12.3 ± 8.3

Body mass index

24.6 ± 4.3

24.6 ± 4.2

Concomitant medications (%)

  

 No other OADs

20.0

18.4

 1 other OAD

36.0

31.5

 2 other OADs

31.0

33.3

  ≥ 3 other OADs

13.0

16.8

  1. OAD, oral antidiabetic drug
  2. Data are presented as the mean ± standard deviation unless otherwise indicated
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us